Obese AdolescentsNCT06779721
Sestrin-2 Levels and Insulin Resistance
An observational study of Obese Adolescents, run by Kayseri City Hospital at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study is to evaluate sestrin-2 levels in children with obesity Read more about this study
- Who is it for?
- Ages 10 to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- Obese Adolescents
- What is being tested?
- Sestrin-2
- How many people
- 89 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 20 Jun 2021to 15 Feb 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: Obese and healthy adolescents who admitted to Kayseri City Hospital
Who may be able to join
- Obese adolescents Body mass index above the 95th percentile BMI Z-score above 2
Who cannot join
- Primary hyperlipidemia Primary liver disease Hypothyroidism Diabetes
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Sestrin-2 Levels and Insulin Resistance in Childhood Obesity
The aim of this study is to evaluate sestrin-2 levels in children with obesity
- Conditions
- Obese Adolescents
- Being tested
- Sestrin-2
- Keywords
- Antioxidant, childhood obesity, insulin resistance, sestrin-2, oxidative stress
- Medical subject headings
- Pediatric Obesity, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sestrin-2Other
Sestrin-2 levels were studied in three different groups
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of sestrin-2 levels in obese and healthy participants
Measured: From enrollment to the end of 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2025
- Study start20 Jun 2021
- Primary completion20 Jan 2022
- Study completion15 Feb 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Obese AdolescentsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 89 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kayseri City Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Pembe Soylu Ustkoyuncu, Kayseri City Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06779721
- Sponsor's protocol ID
- 425/2021
- Status last verified
- Jan 2025
- First submitted
- 13 Jan 2025
- Last updated
- 17 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
Publications
Soylu Ustkoyuncu P, Kocer D. Sestrin-2 levels and insulin resistance in childhood obesity. J Investig Med. 2026 Apr;74(3):254-259. doi: 10.1177/10815589251359311. Epub 2025 Jul 7.
PubMed 40621934
Study at a glance
From the registry record, last updated by the sponsor on 17 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sestrin-2 Levels and Insulin Resistance in Childhood Obesity
- ClinicalTrials.gov ID
- NCT06779721
- Acronym / sponsor ID
- 425/2021
- Conditions
- Obese Adolescents
- Keywords
- Antioxidant, childhood obesity, insulin resistance, sestrin-2, oxidative stress
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 89 participants (actual)
- Lead sponsor
- Kayseri City HospitalOther government
- Study start
- 20 Jun 2021 (actual)
- Primary completion
- 20 Jan 2022 (actual)
- Study completion
- 15 Feb 2022 (actual)
- First posted
- 16 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate sestrin-2 levels in children with obesity
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Ages
- 10 to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- Obese and healthy adolescents who admitted to Kayseri City Hospital
Key inclusion criteria (1 listed)
- Obese adolescents Body mass index above the 95th percentile BMI Z-score above 2
Key exclusion criteria (1 listed)
- Primary hyperlipidemia Primary liver disease Hypothyroidism Diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sestrin-2Sestrin-2 levels were studied in three different groups | Other | – |
Primary outcome
Evaluation of sestrin-2 levels in obese and healthy participants
Time frame: From enrollment to the end of 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jan 2025.
- Derived from this study: PubMed 40621934Soylu Ustkoyuncu P, Kocer D. Sestrin-2 levels and insulin resistance in childhood obesity. J Investig Med. 2026 Apr;74(3):254-259. doi: 10.1177/10815589251359311. Epub 2025 Jul 7.
Related trials for Obese Adolescents
Not yet recruitingObservational study
A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity
Obesity
Not yet recruitingObservational study
Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults
Obesity, Diabetes
Recruiting
Improving Sleep Health and Circadian Timing to Support Cardiometabolic Health in Adolescents
Overweight Adolescents, Sleep
RecruitingPhase 2
Oxytocin for Weight Loss in Adolescents
Obesity, Adolescent, Oxytocin
RecruitingPhase 3
Weight Gain Prevention in Adolescents and Young Adults
Healthy Volunteers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obese Adolescents, run by Kayseri City Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of sestrin-2 levels in obese and healthy participants (time frame: From enrollment to the end of 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06779721, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2025.